Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

Sponsor
NGM Biopharmaceuticals, Inc
Study ID
NCT03392116
Phase
PHASE1
Status
Completed

Conditions

  • Cachexia

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • NGM120 — BIOLOGICAL
    Subcutaneous Injection
  • Placebo — OTHER
    Subcutaneous Injection

Study Details

The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects

Key Dates

First listed
Jan 5, 2018
Start date
Jan 29, 2018
Status verified
Aug 2019
Primary completion
Jan 14, 2019
Completion
Mar 11, 2019

Study Design

Enrollment
92 participants (actual)
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A: NGM120
    Single Dose
  • Placebo Comparator: Part A: Placebo
    Single Dose
  • Experimental: Part B: NGM120
    Multiple Dose
  • Placebo Comparator: Part B: Placebo
    Multiple Dose

Primary Outcome Measure

Part A Arm-Single Dose: Treatment Emergent Adverse events [ Time Frame: 28 days ]

Related Studies